Antenatal corticosteroids: optimal timing and repeated courses

Antenatal corticosteroids have reshaped perinatal care for more than four decades, becoming a cornerstone of obstetric management for women at risk of preterm birth. A course of betamethasone or dexamethasone given to the mother accelerates fetal lung maturation, reduces respiratory distress syndrome, and lowers the risk of intraventricular haemorrhage and neonatal death. The therapy is now embedded in protocols across Australian maternity units.

Yet the apparent simplicity of a single, well-timed injection hides a more complicated clinical picture. Many women who present with threatened preterm labour do not deliver within the expected therapeutic window. Others remain at risk for weeks, prompting clinicians to consider whether to repeat the course. The question of optimal timing, and whether re-dosing improves outcomes or simply adds to fetal glucocorticoid exposure, remains one of the most debated areas in perinatal medicine.

For clinicians in Australia, where geography and population distribution create distinct service patterns, these decisions carry extra weight. A woman in remote Western Australia may be several hours from a tertiary perinatal centre, and steroid timing decisions often happen before retrieval teams arrive. Understanding the evidence around single versus repeat courses directly affects how teams in Perth, Alice Springs, or Cairns plan antenatal transfers.

Discussions about timing and repeat dosing continue at international forums, including meetings of the Federation of Asian and Oceania Perinatal Societies. Resources once gathered for the FAOPS 2020 site continue to anchor that conversation for clinicians across the region.

The biology behind a single antenatal steroid course

The therapeutic effect of antenatal corticosteroids rests on a relatively well-understood mechanism. Glucocorticoids cross the placenta and act on the developing fetal lung, driving surfactant production by type II pneumocytes and accelerating structural maturation of the alveoli. Surfactant reduces alveolar surface tension, allowing the lung to remain open at lower pressures, while the steroids also influence pulmonary vascular development.

A single course, typically two doses of 12 mg betamethasone 24 hours apart or four doses of 6 mg dexamethasone 12 hours apart, achieves maximal benefit roughly 48 hours after the first dose and persists for about seven days before tapering. The same hormonal signal affects other organ systems, including the brain, gut, kidney, and cardiovascular system, which explains both the broad neonatal benefits and the concerns raised about higher-dose or more frequent administration.

The seven-day window of maximum benefit

Observational data and randomised trials have repeatedly confirmed that the seven-day window after a complete course is when neonatal benefit is greatest. Within this period, rates of respiratory distress syndrome fall by roughly half, and severe intraventricular haemorrhage, necrotising enterocolitis, and neonatal mortality all decline. Once the window closes, the protective effect fades, and clinicians must decide whether to accept the loss of benefit or consider a further course.

The "seven-day rule" has become practical shorthand in Australian labour wards. Junior obstetric staff at the Royal Women's in Melbourne or the Mater Mothers' in Brisbane are taught to document the timing of the first dose and to reassess the risk of preterm delivery every 24 hours. If the woman remains undelivered and still at high risk after a week, the conversation shifts toward expectant management or a repeat course.

Timing matters in another way. Steroids given too early, when preterm delivery is unlikely, expose the fetus without delivering the benefit. Steroids given too late, after rapid cervical change or ruptured membranes, may not allow the full 48-hour maturation period before birth. The art of obstetric decision-making is balancing these competing pressures, often with incomplete information.

Why repeat courses became common practice

In the late 1990s and early 2000s, observational studies suggested that women who received more than one course had babies with lower rates of respiratory distress and neonatal intensive care admission. These findings fuelled a permissive approach, and many units adopted weekly or fortnightly re-dosing for women with ongoing risk of preterm birth. The reasoning was straightforward: if a single course helps, additional courses might help more.

This practice was driven partly by the limited options available at the time. Exogenous surfactant replacement was not universally available, and neonatal intensive care capacity in regional centres was stretched. Australian registry data from the ANZNN showed rising use of multiple courses during the early 2000s, particularly among women delivering between 28 and 34 weeks.

Subsequent randomised trials, including the Australasian-led ACTORDS study and the larger MACS trial, began to clarify the picture. Repeat courses did not improve the primary outcomes of death or major disability and were associated with measurable reductions in birthweight and head circumference. The findings shifted consensus away from routine re-dosing toward a more cautious approach.

Weighing neonatal harms and benefits of repeat exposure

The risks of repeat antenatal corticosteroid exposure are subtle but real. Pooled trial data suggest that babies exposed to multiple courses weigh on average 150 to 300 grams less at birth, with proportional reductions in head circumference. Most of this difference resolves by hospital discharge, but concerns remain about longer-term growth and metabolism.

Other signals include a higher risk of neonatal hypoglycaemia, behavioural differences in early childhood, and possible alterations in hypothalamic-pituitary-adrenal axis programming. Australian follow-up of the ACTORDS cohort has contributed reassurance, finding no clear increase in major disability or cerebral palsy at two years, but flagging subtle differences in attention and behaviour that warrant ongoing follow-up.

Alongside these concerns are genuine benefits in specific subgroups. Repeat courses reduce the severity of respiratory distress and the need for mechanical ventilation, particularly in babies born at less than 30 weeks. The clinical calculation therefore depends on gestational age, the strength of the indication, and the time elapsed since the previous course.

How Australian guidelines shape bedside decisions

PSANZ, the Perinatal Society of Australia and New Zealand, has issued recommendations that broadly mirror international consensus while reflecting local practice realities. A single course is recommended for women at risk of preterm delivery between 24 and 34 completed weeks, with optimal benefit when delivery is anticipated within seven days. A single rescue course may be considered if preterm delivery remains likely more than 14 days after the initial dose.

These recommendations are interpreted differently across Australian maternity services. Tertiary centres such as the Women's and Children's in Adelaide or King Edward Memorial in Perth often have well-developed protocols for repeat dosing in carefully selected cases. Smaller regional hospitals tend to adopt a more conservative stance, in part because retrieval logistics make it harder to predict the exact timing of delivery.

Local practice is also shaped by Australia's universal health insurance framework and the role of Medicare-funded obstetric care. Women in public hospital antenatal clinics are typically managed under shared-care or midwifery-led models, and corticosteroid decisions are made jointly between obstetric and neonatal teams. Communication between referring and receiving hospitals is integral to planning.

Practical challenges in remote and rural Australia

Geography shapes steroid decisions in ways that rarely appear in international guidelines. A woman at 28 weeks presenting with threatened preterm labour in a town like Mount Isa, Broome, or Burnie may need to be retrieved by air to a tertiary centre several hundred kilometres away. The receiving team needs time to prepare, and the referring team may give the first steroid dose before transfer.

This creates a tension. Australian clinicians are mindful of avoiding unnecessary fetal exposure, but the uncertainty of retrieval timelines and weather delays often pushes the decision toward earlier dosing. Some services have adopted protocols for women between 28 and 32 weeks who require fixed-wing transfer, accepting a small degree of overtreatment to ensure that babies born during retrieval receive the benefit.

Telehealth and regional outreach programmes have reduced some of this uncertainty. Tertiary centres in Darwin and Townsville now provide real-time ultrasound review to smaller sites, allowing more accurate assessment of cervical length and fetal wellbeing. These developments have helped Australian teams refine, rather than abandon, the use of antenatal corticosteroids in remote settings. For those interested in related neonatal nutritional challenges, a resource on neonatal intestinal failure and parenteral nutrition provides useful context on the longer-term support these preterm infants often require.

Emerging evidence and ongoing clinical trials

The evidence base for antenatal corticosteroids continues to evolve. Recent trials have examined lower-dose regimens, alternative corticosteroids such as hydrocortisone for specific indications, and biomarker-guided timing. Australian researchers have contributed through perinatal research networks and trials registered with the Australian New Zealand Clinical Trials Registry.

One area of active investigation is whether a single rescue course, given only when delivery appears imminent, can preserve the benefits of repeat dosing while limiting total steroid exposure. Another is the long-term neurodevelopmental follow-up of children exposed to multiple courses, with Australian cohorts now reaching school age.

There is also renewed interest in the use of antenatal corticosteroids at the borderline of viability, between 22 and 24 weeks, where decisions are deeply value-laden and practice varies considerably between centres. As evidence matures, Australian teams will refine their protocols further, balancing the well-established benefits of a timely first course with the more nuanced calculus around rescue and repeat dosing.

When a repeat course may be considered

• Gestational age below 34 weeks
• More than 14 days since the initial course
• High likelihood of preterm delivery within 7 days
• No prior repeat dosing in the current pregnancy

When repeat dosing is usually avoided

• Estimated fetal weight already below the 10th centile
• A rescue dose already given within the current pregnancy
• Maternal condition that increases glucocorticoid risk
• Delivery no longer considered imminent after reassessment

For clinicians managing women at risk of preterm birth, the practical message is clear: time the first course carefully, reassess at the seven-day mark, and reserve any repeat dose for situations where benefit clearly outweighs the small but measurable risks. Australian teams are encouraged to draw on local PSANZ guidance, regional retrieval expertise, and ongoing trial data to support individualised decisions. Sharing case experience and contributing to follow-up studies will help refine practice for the next generation of preterm infants.